Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7Z4M0
UPID:
RE114_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z4M0
Background:
Meiotic recombination protein REC114 plays a pivotal role in the process of meiosis, specifically required for DNA double-strand breaks (DSBs) formation in unsynapsed regions. This is achieved through a complex with IHO1 and MEI4, activating DSBs formation, a critical step for synapsis completion.
Therapeutic significance:
The involvement of Meiotic recombination protein REC114 in Oocyte/zygote/embryo maturation arrest 10, an autosomal recessive infertility disorder, highlights its potential as a target for therapeutic intervention. Understanding the role of Meiotic recombination protein REC114 could open doors to potential therapeutic strategies.